Ahmedabad-based Torrent Pharma on Tuesday announced that it will launch MSD (Merck & Co., US) and Ridgeback’s Molnupiravir – an oral anti-viral drug to treat mild to moderate Covid19 under the brand name Molnutor in India.
Torrent Pharma said that it is involved in a non-exclusive voluntary licensing pact with MSD which has granted the rights of manufacturing, distributing and marketing of the drug in above 100 low and middle-income markets including India.
Based on the review of clinical trial, the Drugs Controller General of India (DGCI) approved the drug to treat adult Covid patients for restricted emergency use in the country, the company further said.
The executive director of Torrent Pharmaceuticals Limited, Aman Mehta said, “We are pleased to partner with MSD to bring Molnupiravir to patients across India. Molnupiravir will be an important addition to our healthcare system’s ammunition in the fight against Covid-19.”
